XTLB Overview

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Wall Street analysts forecast XTLB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTLB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

X T L Biopharmaceuticals Ltd revenue for the last quarter amounts to 289.00K USD, decreased

X T L Biopharmaceuticals Ltd. EPS for the last quarter amounts to -0.00 USD, decreased

X T L Biopharmaceuticals Ltd (XTLB) has 4 emplpoyees as of March 31 2026.

Today XTLB has the market capitalization of 6.17M USD.